Lv2
110 积分 2024-04-19 加入
siRNA: Mechanism of action, challenges, and therapeutic approaches
10天前
已完结
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors
2个月前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
2个月前
已完结
Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial
3个月前
已完结
Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study
3个月前
已完结
Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial
3个月前
已完结
Analysis of the Complement System in the Clinical Immunology Laboratory
5个月前
已完结
Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier
6个月前
已完结
Antibody-oligonucleotide conjugates in cancer therapy: Potential and Promise
7个月前
已关闭
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
7个月前
已完结
皖公网安备34019202002308
